Evidence map›Paper›PMID 19956730›Full record

ArticlePloS one2009

Detection of pancreatic carcinomas by imaging lactose-binding protein expression in peritumoral pancreas using [18F]fluoroethyl-deoxylactose PET/CT.

Leo Garcia Flores, Susanna Bertolini, Hsin Hsin Yeh, Daniel Young, Uday Mukhopadhyay, Ashutosh Pal, Yunming Ying, Andrei Volgin, Aleksandr Shavrin, Suren Soghomonyan and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. The clinical application ofTranslational cancer research · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Positron emission tomography (PET) imaging with (18)F-based radiotracers.American journal of nuclear medicine and molecular imaging · 2012
    Article
  11. Plectin-1 as a novel biomarker for pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Leo Garcia FloresDepartment of Experimental Diagnostic Imaging, Center for Advanced Biomedical Imaging Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Susanna Bertolini
Hsin Hsin Yeh
Daniel Young
Uday Mukhopadhyay
Ashutosh Pal
Yunming Ying
Andrei Volgin
Aleksandr Shavrin
Suren Soghomonyan
William Tong
William Bornmann
Mian M Alauddin
Craig Logsdon
Juri G Gelovani
The University of Texas MD Anderson Cancer Center · USImaging Center · US

Funding

Experimental Cancer Imaging Research Program (ECIRP)U24CA126577 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GELOVANI, JURI GEORGE, HAZLE, JOHN D. · 2007 to 2011
$2.2M
NCI NIH HHS U24 CA126577NCI NIH HHS U24 CA126577-01
6 · The paper itself

Abstract

backgroundEarly diagnosis of pancreatic carcinoma with highly sensitive diagnostic imaging methods could save lives of many thousands of patients, because early detection increases resectability and survival rates. Current non-invasive diagnostic imaging techniques have inadequate resolution and sensitivity for detection of small size ( approximately 2-3 mm) early pancreatic carcinoma lesions. Therefore, we have assessed the efficacy of positron emission tomography and computer tomography (PET/CT) imaging with beta-O-D-galactopyranosyl-(1,4')-2'-deoxy-2'-[(18)F]fluoroethyl-D-glucopyranose ([(18)F]FEDL) for detection of less than 3 mm orthotopic xenografts of L3.6pl pancreatic carcinomas in mice. [(18)F]FEDL is a novel radioligand of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), which is overexpressed in peritumoral pancreatic acinar cells. METHODOLOGY/PRINCIPAL

findingsDynamic PET/CT imaging demonstrated rapid accumulation of [(18)F]FEDL in peritumoral pancreatic tissue (4.04+/-2.06%ID/g), bi-exponential blood clearance with half-lives of 1.65+/-0.50 min and 14.14+/-3.60 min, and rapid elimination from other organs and tissues, predominantly by renal clearance. Using model-independent graphical analysis of dynamic PET data, the average distribution volume ratio (DVR) for [(18)F]FEDL in peritumoral pancreatic tissue was estimated as 3.57+/-0.60 and 0.94+/-0.72 in sham-operated control pancreas. Comparative analysis of quantitative autoradiographic images and densitometry of immunohistochemically stained and co-registered adjacent tissue sections demonstrated a strong linear correlation between the magnitude of [(18)F]FEDL binding and HIP/PAP expression in corresponding regions (r = 0.88). The in situ analysis demonstrated that at least a 2-4 fold apparent lesion size amplification was achieved for submillimeter tumors and to nearly half a murine pancreas for tumors larger than 3 mm. CONCLUSION/SIGNIFICANCE: We have demonstrated the feasibility of detection of early pancreatic tumors by non-invasive imaging with [(18)F]FEDL PET/CT of tumor biomarker HIP/PAP over-expressed in peritumoral pancreatic tissue. Non-invasive non-invasive detection of early pancreatic carcinomas with [(18)F]FEDL PET/CT imaging should aid the guidance of biopsies and additional imaging procedures, facilitate the resectability and improve the overall prognosis.

Indexed as

AnimalsAntigens, NeoplasmBiomarkers, TumorCarcinomaCarcinoma, Acinar CellFluorine RadioisotopesLactoseLectins, C-TypeLigandsMiceModels, BiologicalNeoplasm TransplantationPancreasPancreatic NeoplasmsPancreatitis-Associated ProteinsPositron-Emission TomographyAntigens, NeoplasmBiomarkers, TumorFluorine RadioisotopesLactoseLectins, C-TypeLigandsO-galactopyranosyl-(1-4')-2'-deoxy-2'-fluoroethylglucopyranosePancreatitis-Associated ProteinsRadiopharmaceuticalsREG3A protein, human

Identifiers

PMID19956730
PMCPMC2776527
OpenAlexW2117665515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.